Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

1. CIRSE Standards of Practice on Peri-operative Anticoagulation Management During Interventional Radiology Procedures

CIRSE Standards of Practice on Peri-operative Anticoagulation Management During Interventional Radiology Procedures CIRSE Standards of Practice on Peri-operative Anticoagulation Management During Interventional Radiology Procedures

2021 Cardiovascular and Interventional Radiological Society of Europe

2. Anticoagulant Treatment for Splanchnic Vein Thrombosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis

Anticoagulant Treatment for Splanchnic Vein Thrombosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis Anticoagulant Treatment for Splanchnic Vein Thrombosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation (...) for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Thromb Haemost Actions . 2021 Feb 1. doi: 10.1055/s-0040-1722192. Online ahead of print. Anticoagulant Treatment for Splanchnic Vein Thrombosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis , , , , , , , , , Affiliations Expand Affiliations 1 Department

2021 EvidenceUpdates

3. DOAC Dipstick for detecting direct oral anticoagulants

DOAC Dipstick for detecting direct oral anticoagulants DOAC Dipstick for detecting direct oral anticoagulants Medtech innovation briefing Published: 2 February 2021 www.nice.org.uk/guidance/mib248 pathways Summary Summary • The technology technology described in this briefing is the DOASENSE DOAC Dipstick. It is used for detecting direct oral anticoagulants (DOACs) in urine. • The innovative aspects innovative aspects are that the technology is a point-of-care test with results available within (...) . • The cost cost of the DOAC Dipstick is £15 per strip (excluding VAT). © NICE 2021. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 1 of 13The technology The technology The DOAC Dipstick (DOASENSE GmbH) is a single-use, point-of-care dipstick test that is used to detect direct oral anticoagulants (DOACs) in urine. The urine dipstick test detects DOACs (both factor Xa inhibitors and thrombin inhibitors) based on colour-changing

2021 National Institute for Health and Clinical Excellence - Advice

4. Effect of oral anticoagulant use on surgical delay and mortality in hip fracture

Effect of oral anticoagulant use on surgical delay and mortality in hip fracture Effect of oral anticoagulant use on surgical delay and mortality in hip fracture - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. National Institutes of Health National Library of Medicine National (...) Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Meta-Analysis Bone Joint J Actions . 2021 Feb;103-B(2):222-233. doi: 10.1302/0301-620X.103B2.BJJ-2020-0583.R2. Effect of oral anticoagulant use on surgical delay and mortality in hip fracture , , , , , , , Affiliations Expand Affiliations 1 Department of Surgery, Section of Orthopaedic Surgery, University of Calgary, Calgary, Alberta

2021 EvidenceUpdates

5. Anticoagulant and Antiplatelet Therapy

Anticoagulant and Antiplatelet Therapy 2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee | Journal of the American College of Cardiology Search Quick Search anywhere Enter Search Terms Search Quick Search in Journals Enter (...) Search Terms Search Quick Search in Journals Enter Search Terms Search Quick Search in Journals Enter Search Terms Search Quick Search in Journals Enter Search Terms Search Quick Search in Journals Enter Search Terms Search Quick Search in Journals Enter Search Terms Search Quick Search in Journals Enter Search Terms Search Quick Search in Journals Enter Search Terms Search › › › 2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation

2021 American College of Cardiology

6. Poor evidence of direct anticoagulant (DOAC), DOAC and increased thrombosis without APS and COVID-19

Poor evidence of direct anticoagulant (DOAC), DOAC and increased thrombosis without APS and COVID-19 Page 52 · MED CHECK December 2020/ Vol.6 No.19 C N o 19 M ED HECK 2 0 2 0 Editorial Amateurism Review Poor evidence of direct anticoagulant (DOAC) DOAC and increased thrombosis without APS Candidates of New Products COVID-19 Vaccine Candidates Editorial Amateurism Review Warfarin is the standard treatment for non-valvular atrial fibrillation DOAC may induce more thrombosis in patients without (...) Introduction Prevalence of patients with non-valvular atrial fibrillation increases with age [1,2]. Incidence of stroke and coronary heart disease, cardiovascular mortality and overall mortality increases with each additional risk The usefulness of direct anticoagulants (DOACs) has not been proven Translated and revised from Med Check(in Japanese) Mar 2020 ; 20 (88):30-34 Summary ? Until 2010, warfarin, a vitamin K antagonist, was the only oral anticoagulant for the management of non-valvular atrial

2021 Med Check - The Informed Prescriber

7. Thrombosis Canada Guidance on COVID-19 Vaccines and Anticoagulation

Thrombosis Canada Guidance on COVID-19 Vaccines and Anticoagulation FOR IMMEDIATE RELEASE: THROMBOSIS CANADA ENCOURAGES PATIENTS ON ANTICOAGULATION TO GET THE COVID-19 VACCINE Thrombosis Canada guidance is that anticoagulant therapy should not be a barrier to getting vaccinated for the estimated 1 million Canadians on anticoagulants Toronto, Ontario (December 22, 2020) – As COVID-19 vaccine distribution and administration ramps up in Canada, physicians and patients are asking about managing (...) vaccination in people who are receiving anticoagulant (blood thinning) therapy. This issue is important for an estimated 1 million Canadians who are receiving anticoagulant therapy, many of whom are elderly and are likely to be at higher risk for coronavirus-related health problems. It is important to emphasize that anticoagulant therapy should not be a barrier to the administration of the coronavirus vaccine. In our view, any bleeding risk due to anticoagulant therapy that may result in a hematoma

2021 Thrombosis Interest Group of Canada

8. Effectiveness and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in patients with left ventricular thrombus: A meta-analysis

Effectiveness and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in patients with left ventricular thrombus: A meta-analysis Effectiveness and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in patients with left ventricular thrombus: A meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) Jan;197:185-191. doi: 10.1016/j.thromres.2020.11.018. Epub 2020 Nov 20. Effectiveness and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in patients with left ventricular thrombus: A meta-analysis , , , , Affiliations Expand Affiliations 1 Department of Cardiac Surgery, Shengjing Hospital of China Medical University, Shenyang, China. Electronic address: zhouk@sj-hospital.org. 2 Department of Ultrasound, Shengjing Hospital of China Medical University, Shenyang, China

2021 EvidenceUpdates

9. Management of anticoagulant services (Covid-19)

Management of anticoagulant services (Covid-19) Publications approval reference: 001559 Specialty guides for patient management during the coronavirus pandemic Clinical guide for the management of anticoagulant services during the coronavirus pandemic November 2020 As healthcare professionals we all have general responsibilities in relation to coronavirus and for these we should seek and act on national and local guidelines. We also have a specific responsibility to ensure that anticoagulant (...) care continues with the minimum burden on the NHS. We must engage with management and clinical teams planning the local response in our hospitals and across primary care. Anticoagulant services may not seem to be in the frontline with coronavirus but we do have a key role in continuing to keep patients on anticoagulants as safe as possible; this must be planned. In response to pressures on the NHS, the way we deliver anticoagulants may need to change. We should seek the best local solutions

2021 NHS England

10. Twice- or Once-Daily Dosing of Direct Oral Anticoagulants, a systematic review and meta-analysis

Twice- or Once-Daily Dosing of Direct Oral Anticoagulants, a systematic review and meta-analysis Twice- or Once-Daily Dosing of Direct Oral Anticoagulants, a systematic review and meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health (...) of Direct Oral Anticoagulants, a systematic review and meta-analysis , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Université de Lyon, Université Lyon 1, CNRS, Laboratoire de Biométrie et Biologie Evolutive UMR 5558, F-69622 Villeurbanne, France; Service de Médecine Interne et Vasculaire, Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France. Electronic address: sabine.mainbourg@chu-lyon.fr. 2 Université de Lyon, Université Lyon 1, CNRS, Laboratoire de Biométrie et Biologie Evolutive

2020 EvidenceUpdates

11. Risk of developing diabetes in patients with atrial fibrillation taking non-vitamin K antagonist oral anticoagulants or warfarin: A nationwide cohort study Full Text available with Trip Pro

Risk of developing diabetes in patients with atrial fibrillation taking non-vitamin K antagonist oral anticoagulants or warfarin: A nationwide cohort study Risk of developing diabetes in patients with atrial fibrillation taking non-vitamin K antagonist oral anticoagulants or warfarin: A nationwide cohort study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) . 2020 Nov 2. doi: 10.1111/dom.14243. Online ahead of print. Risk of developing diabetes in patients with atrial fibrillation taking non-vitamin K antagonist oral anticoagulants or warfarin: A nationwide cohort study , , , , , , , , , Affiliations Expand Affiliations 1 Departments of Family Medicine and Medical Research, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan. 2 Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan

2020 EvidenceUpdates

12. Meta-Analysis of Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin According to Time in Therapeutic Range in Atrial Fibrillation

Meta-Analysis of Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin According to Time in Therapeutic Range in Atrial Fibrillation Meta-Analysis of Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin According to Time in Therapeutic Range in Atrial Fibrillation - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily (...) )31202-9. doi: 10.1016/j.amjcard.2020.10.064. Online ahead of print. Meta-Analysis of Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin According to Time in Therapeutic Range in Atrial Fibrillation , , , , , Affiliations Expand Affiliations 1 University of Toronto, Toronto, Canada. 2 Department of Medicine, University of Toronto, Toronto, Canada; Peter Munk Cardiac Centre, University Health Network, Toronto, Canada. Electronic address: andrew.ha@uhn.ca. 3 Department of Medicine

2020 EvidenceUpdates

13. Satisfaction of Patients with Nonvitamin K Anticoagulants Compared to Vitamin K Antagonists: a Systematic Review and Meta-analysis

Satisfaction of Patients with Nonvitamin K Anticoagulants Compared to Vitamin K Antagonists: a Systematic Review and Meta-analysis Satisfaction of Patients with Nonvitamin K Anticoagulants Compared to Vitamin K Antagonists: a Systematic Review and Meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging (...) of print. Satisfaction of Patients with Nonvitamin K Anticoagulants Compared to Vitamin K Antagonists: a Systematic Review and Meta-analysis , , , , , , , Affiliations Expand Affiliations 1 Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. 2 Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. 3 Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. 4 Centro de Estudos de Medicina

2020 EvidenceUpdates

14. The Use of Therapeutic-Dose Anticoagulation and Its Effect on Mortality in Patients With COVID-19: A Systematic Review Full Text available with Trip Pro

The Use of Therapeutic-Dose Anticoagulation and Its Effect on Mortality in Patients With COVID-19: A Systematic Review The Use of Therapeutic-Dose Anticoagulation and Its Effect on Mortality in Patients With COVID-19: A Systematic Review - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving (...) of Therapeutic-Dose Anticoagulation and Its Effect on Mortality in Patients With COVID-19: A Systematic Review , , Affiliations Expand Affiliations 1 Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin General Hospital, Bandung, Indonesia. 2 Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin General Hospital, Bandung, Indonesia. PMID: 33079569 DOI: Free article Item in Clipboard

2020 EvidenceUpdates

15. Warfarin and other anticoagulants: monitoring of patients during the COVID-19 pandemic

Warfarin and other anticoagulants: monitoring of patients during the COVID-19 pandemic Warfarin and other anticoagulants: monitoring of patients during the COVID-19 pandemic - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Show or hide search Search on GOV.UK Search National restrictions (...) in England from 5 November Take action now for new rules in 2021 Warfarin and other anticoagulants: monitoring of patients during the COVID-19 pandemic Guidance has been published on monitoring of patients on warfarin and other anticoagulants during the COVID-19 pandemic. Published 22 October 2020 From: Therapeutic area: Following concerns raised by clinicians during the coronavirus (COVID-19) pandemic, we have issued regarding the safe use of warfarin and other anticoagulants. This advice has been

2020 MHRA Drug Safety Update

16. Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID) Full Text available with Trip Pro

Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID) Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving (...) versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID) , , , , , , Affiliations Expand Affiliations 1 Division of Emergency Medicine, Department of Internal Medicine, Ribeirão Preto School of Medicine, São Paulo University, Ribeirão Preto, SP, Brazil. 2 Hospital Estadual de Américo Brasiliense, Ribeirão Preto School of Medicine, São Paulo University, Ribeirão Preto, SP, Brazil. 3 Division of Emergency Medicine, Department of Internal Medicine

2020 EvidenceUpdates

17. The increased risk of bleeding due to drug-drug interactions in patients administered direct oral anticoagulants

The increased risk of bleeding due to drug-drug interactions in patients administered direct oral anticoagulants The increased risk of bleeding due to drug-drug interactions in patients administered direct oral anticoagulants - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get (...) to drug-drug interactions in patients administered direct oral anticoagulants , , , , , , , Affiliations Expand Affiliations 1 Department of Internal Medicine, Seoul National University, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. 2 SCH Biomedical Informatics Research Unit, Seoul, Republic of Korea. 3 Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Republic of Korea. 4 Department of Pediatrics

2020 EvidenceUpdates

18. Covid-19 patients who are not hospitalised: anticoagulation is rarely justified Full Text available with Trip Pro

Covid-19 patients who are not hospitalised: anticoagulation is rarely justified Prescrire IN ENGLISH - Spotlight ''Covid-19 patients who are not hospitalised: anticoagulation is rarely justified'', 24 September 2020 {1} {1} {1} | | > > > Covid-19 patients who are not hospitalised: anticoagulation is rarely justified Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |    (...) |  Spotlight Covid-19 patients who are not hospitalised: anticoagulation is rarely justified NEWS UPDATE The risk of thromboembolism in patients with a mild to moderate form of covid-19 is unclear and probably varies greatly between patients. Is anticoagulation justified to prevent deep vein thrombosis in patients with covid-19 who are not hospitalised? Arterial or venous thromboembolism is a common complication in patients hospitalised in intensive care for a severe form of covid-19

2020 Prescrire

19. Antithrombotic Therapy After Transcatheter Aortic Valve Implantation in Patients with Long-Term Indication for Anticoagulation: Systematic Review and Meta-Analysis Full Text available with Trip Pro

Antithrombotic Therapy After Transcatheter Aortic Valve Implantation in Patients with Long-Term Indication for Anticoagulation: Systematic Review and Meta-Analysis Antithrombotic Therapy After Transcatheter Aortic Valve Implantation in Patients with Long-Term Indication for Anticoagulation: Systematic Review and Meta-Analysis | medRxiv Search for this keyword Antithrombotic Therapy After Transcatheter Aortic Valve Implantation in Patients with Long-Term Indication for Anticoagulation (...) oral anticoagulation (OAC). Methods: We systematically searched PubMed, Embase, and Cochrane databases for interventional and observational studies comparing OAC to OAC plus single antiplatelet therapy (SAPT). Results: Five studies were included (four registry-based and one randomized controlled trial), comprising a total of 1318 patients. Our meta-analysis revealed lower rates of severe bleeding (pooled odds ratio [OR] 0.46 [0.31, 0.69], P<0.01, I2=0%) and major bleeding (pooled OR 0.46 [0.27,0.79

2020 Cold Spring Harbor Laboratory

20. Major bleeding risk with non-vitamin K antagonist oral anticoagulant vs. aspirin in heart failure: network meta-analysis Full Text available with Trip Pro

Major bleeding risk with non-vitamin K antagonist oral anticoagulant vs. aspirin in heart failure: network meta-analysis Major bleeding risk with non‐vitamin K antagonist oral anticoagulant vs. aspirin in heart failure: network meta‐analysis - Huang - 2020 - ESC Heart Failure - Wiley Online Library Working off-campus? Learn about our By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term Original Research Article Open (...) Access Major bleeding risk with non‐vitamin K antagonist oral anticoagulant vs. aspirin in heart failure: network meta‐analysis Department of Neurology, College of Medicine, Chang Gung University, Chang Gung Memorial Hospital, Keelung Branch, No.222, Mai‐Jin Road, Keelung, 204 Taiwan UCLA Stroke Center, University of California, 300 Medical Plaza Driveway B200, Los Angeles, CA, 90095 USA Institute of Population Health Sciences, National Health Research Institutes, No. 35, Keyan Road, Zhunan, Miaoli

2020 ESC heart failure